Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc (FEMY) delivers innovative solutions in women's healthcare through minimally invasive diagnostic tools and therapeutic devices. This news hub provides investors and industry observers with timely updates on corporate developments, regulatory milestones, and clinical advancements.
Access comprehensive coverage of FEMY's progress in fertility treatments, non-surgical birth control technologies, and companion diagnostics. Our curated news collection features official press releases, partnership announcements, and product clearance updates from global health authorities.
Key focus areas include FDA regulatory developments, international market expansions, and research breakthroughs. All content is sourced directly from company communications and verified financial channels to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined tracking of Femasys' biomedical innovations and corporate announcements. For complete investment analysis, combine these updates with SEC filings and market performance data available through Stock Titan's research tools.
Femasys (NASDAQ:FEMY) has secured regulatory approvals in Australia and New Zealand for two key products in its women's health portfolio. The approvals cover FemaSeed®, a first-line intratubal insemination treatment for infertility, and FemVue®, a diagnostic evaluation tool.
According to CEO Kathy Lee-Sepsick, these regulatory milestones represent significant progress in expanding global access to the company's innovative infertility solutions. The approvals are expected to create new commercial opportunities and support revenue growth while expanding Femasys's global market presence.
Femasys (NASDAQ:FEMY) has achieved a historic milestone with the European CE mark approval for its FemBloc® System, the world's first non-surgical permanent birth control solution. The Class III FemBloc blended polymer component received certification under EU MDR 2017/745, following the earlier approval of its delivery system component in March 2025.
The FemBloc System can now be marketed across the European Economic Area, including 27 EU member states and 3 European Free Trade Association countries. The company plans to launch commercial distribution initially in Spain through existing partners while pursuing additional country approvals and continuing its FDA IDE-approved pivotal trial for U.S. approval.
Femasys (NASDAQ: FEMY), a biomedical company focused on women's health, has announced plans for a public offering of common stock alongside a concurrent private placement. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares from the public offering. Current institutional stockholders, directors, and officers have shown interest in participating in the private placement.
Jones will serve as the sole book-running manager for the public offering and placement agent for the private placement. Femasys plans to use the proceeds for commercial expansion, product development, corporate purposes, capital expenditures, and working capital. The public offering will be made through a previously filed S-3 Registration Statement, while the private placement will rely on Securities Act exemptions.
Femasys Inc. (NASDAQ: FEMY) reported financial results for 2024 and provided corporate updates. Key highlights include FemBloc® permanent birth control system approval in Europe and new distribution partnerships in Spain. The company's sales increased 52.0% to $1.63 million in 2024, while net loss widened to $18.82 million ($0.85 per share).
Notable achievements include partnerships with CNY Fertility, HRC Fertility, and Boston IVF for FemaSeed® distribution, along with UK and Israeli regulatory approvals. R&D expenses rose 14.0% to $8.22 million. The company ended 2024 with $3.5 million in cash and raised an additional $5.4 million post-year-end, expecting to fund operations into Q3 2025.
Femasys (NASDAQ: FEMY) has announced a strategic partnership with CNY Fertility, a national provider of fertility services, to offer its FemaSeed intratubal insemination product across CNY's network of 11 locations. The partnership aims to expand access and market share for Femasys's first-line infertility treatment option.
CNY Fertility, recognized as a prominent infertility group in the United States, will integrate FemaSeed into their comprehensive fertility solutions portfolio. This collaboration aligns with CNY Fertility's mission to provide affordable, high-quality fertility treatments while expanding treatment options for patients seeking to grow their families.
Femasys Inc. (FEMY) has secured its first global distribution partnerships for FemBloc®, a non-surgical permanent birth control solution, in Spain. The company has partnered with Comercial Medico Quirurigca, SA (CMQ) for northern Spain and Durgalab for the southern region.
These partnerships represent Femasys's first EU distributors and mark the initial global commercialization of FemBloc®. Both distribution partners have previous experience with Conceptus Essure product, positioning them strategically for marketing FemBloc® as a new advancement in non-surgical permanent birth control.